Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial Of Sunitinib Administered Daily For 4 Weeks, Followed By 2-Week Rest Vs. 2-Week On And 1-Week Off In Metastatic Renal Cell Carcinoma

NCT00570882 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT00570882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00570882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial Of Sunitinib Administered Daily For 4 Weeks, Followed By 2-Week Rest Vs. 2-Week On And 1-Week Off In Metastatic Renal Cell Carcinoma
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
June 30, 2014
Enrollment
76 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma